Trial Profile
A Retrospective study to evaluate the efficacy and cost associated with Sucroferric Oxyhydroxide treatment in hemodialysis patients with persistent hyperphosphatemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 May 2018
Price :
$35
*
At a glance
- Drugs Sucroferric oxyhydroxide (Primary)
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- 24 May 2018 New trial record
- 23 May 2018 Results (n=16) presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research